Codex DNA Inc
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $1.8203
- Today's High:
- $2.025
- Open Price:
- $1.84
- 52W Low:
- $1.08
- 52W High:
- $3.83
- Prev. Close:
- $1.85
- Volume:
- 129243
Company Statistics
- Market Cap.:
- $38.38 million
- Book Value:
- 1.806
- Revenue TTM:
- $21.04 million
- Operating Margin TTM:
- -239.49%
- Gross Profit TTM:
- $4.30 million
- Profit Margin:
- -251.05%
- Return on Assets TTM:
- -29.63%
- Return on Equity TTM:
- -67.7%
Company Profile
Codex DNA Inc had its IPO on 2021-06-18 under the ticker symbol DNAY.
The company operates in the Healthcare sector and Healthcare Equipment & Supplies industry. Codex DNA Inc has a staff strength of 212 employees.
Stock update
Shares of Codex DNA Inc opened at $1.84 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $1.82 - $2.03, and closed at $2.
This is a +8.11% increase from the previous day's closing price.
A total volume of 129,243 shares were traded at the close of the day’s session.
In the last one week, shares of Codex DNA Inc have increased by +14.94%.
Codex DNA Inc's Key Ratios
Codex DNA Inc has a market cap of $38.38 million, indicating a price to book ratio of 0.6535 and a price to sales ratio of 1.6834.
In the last 12-months Codex DNA Inc’s revenue was $21.04 million with a gross profit of $4.30 million and an EBITDA of $-48951000. The EBITDA ratio measures Codex DNA Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Codex DNA Inc’s operating margin was -239.49% while its return on assets stood at -29.63% with a return of equity of -67.7%.
In Q3, Codex DNA Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 139.6%.
Codex DNA Inc’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
Its diluted EPS in the last 12-months stands at $-1.843 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Codex DNA Inc’s profitability.
Codex DNA Inc stock is trading at a EV to sales ratio of 0.3069 and a EV to EBITDA ratio of -0.1318. Its price to sales ratio in the trailing 12-months stood at 1.6834.
Codex DNA Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $88.14 million
- Total Liabilities
- $12.81 million
- Operating Cash Flow
- $13.72 million
- Capital Expenditure
- $3.71 million
- Dividend Payout Ratio
- 0%
Codex DNA Inc ended 2024 with $88.14 million in total assets and $0 in total liabilities. Its intangible assets were valued at $88.14 million while shareholder equity stood at $-105609000.00.
Codex DNA Inc ended 2024 with $0 in deferred long-term liabilities, $12.81 million in other current liabilities, 5000.00 in common stock, $-105609000.00 in retained earnings and $14.89 million in goodwill. Its cash balance stood at $24.74 million and cash and short-term investments were $24.74 million. The company’s total short-term debt was $733,000 while long-term debt stood at $19.47 million.
Codex DNA Inc’s total current assets stands at $62.19 million while long-term investments were $0 and short-term investments were $25.01 million. Its net receivables were $5.66 million compared to accounts payable of $1.62 million and inventory worth $2.20 million.
In 2024, Codex DNA Inc's operating cash flow was $13.72 million while its capital expenditure stood at $3.71 million.
Comparatively, Codex DNA Inc paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $2
- 52-Week High
- $3.83
- 52-Week Low
- $1.08
- Analyst Target Price
- $6.5
Codex DNA Inc stock is currently trading at $2 per share. It touched a 52-week high of $3.83 and a 52-week low of $3.83. Analysts tracking the stock have a 12-month average target price of $6.5.
Its 50-day moving average was $1.73 and 200-day moving average was $1.96 The short ratio stood at 1.89 indicating a short percent outstanding of 0%.
Around 3713.7% of the company’s stock are held by insiders while 4357.9% are held by institutions.
Frequently Asked Questions About Codex DNA Inc
Similar Industry Stocks (Healthcare Equipment & Supplies)
Most Active
Top Gainers
Top Losers
About
Codex DNA, Inc., a synthetic biology company, manufactures and sells synthetic biology instruments, reagents, and associated products and related services, primarily to pharmaceutical and academic laboratories worldwide. Its solutions include BioXp system that empowers researchers to go from a digital DNA sequence to endpoint-ready synthetic DNA; BioXp portal, an online portal that offers an intuitive guided workflow and design tools for building new DNA sequences and assembling them into vectors of choice; BioXp kits that contain building blocks and reagents, including its Gibson Assembly branded reagents, for specific synthetic biology workflow applications; Cloud-based scripts; Benchtop reagents that contain all the reagents necessary to proceed with a specific synthetic biology workflow on the benchtop using products generated on the BioXp system; Biofoundry Services, which enable a customer to order and receive the BioXp system endpoint-ready products, such as genes, clones, cell-free amplified DNA, and variant libraries; and short oligo ligation assembly enzymatic DNA synthesis. It also serves government institutions, contract research organizations, and synthetic biology companies. The company was formerly known as SGI-DNA, Inc. and changed its name to Codex DNA, Inc. in March 2020. Codex DNA, Inc. was incorporated in 2011 and is headquartered in San Diego, California.